Author

R. R. Flavell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 1

Frequent Co-Authors

B. Liu· 2 shared J. He· 2 shared S. Bidlingmaier· 2 shared Y. Seo· 2 shared Y. Su· 2 shared A. Bidkar· 1 shared A. Li· 1 shared A. P. Bidkar· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

B. Liu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

J. Li, T. Huang, J. Hua, Q. Wang, Y. Su, P. Chen, S. Bidlingmaier, A. Li, Z. Xie, A. Bidkar, S. Shen, W. Shi, Y. Seo, R. R. Flavell, D. Gioeli, , J. He

This paper develops and tests a CD46-targeted alpha radioimmunotherapy, 212Pb-TCMC-YS5, showing potent tumor growth inhibition and survival improvement in multiple prostate cancer models.

bioRxiv · Oct 14, 2022 · PreprintBioengineering

Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy

A. P. Bidkar, S. Wang, K. N. Bobba, E. Chan, S. Bidlingmaier, E. A. Egusa, R. Peter, U. Ali, N. Meher, A. Wadhwa, S. Dhrona, D. Beckford-Vera, Y. Su, R. Tang, L. Zhang, , R. R. Flavell

This study develops and evaluates [225Ac]DOTA-YS5, a radioimmunotherapy for prostate cancer, showing high efficacy in xenograft models but nephrotoxicity at higher doses.

bioRxiv · Oct 13, 2022 · PreprintCancer Biology